Literature DB >> 11795409

Pharmacological issues in the treatment of tuberculosis.

C A Peloquin1.   

Abstract

A thorough review of the clinical trial data combined with new in vitro experimental information may make the optimization of dosages of TB drugs possible. Several factors can affect the selection and dosage of TB drugs including hepatic and renal impairment, pregnancy, duration of disease before treatment, and extent of debilitation. Drug interactions and pharmacodynamics must be considered, and their roles are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11795409     DOI: 10.1111/j.1749-6632.2001.tb11374.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  13 in total

Review 1.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

Review 2.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

3.  Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis.

Authors:  Sharon Y Wong; Jong Seok Lee; Hyun Kyung Kwak; Laura E Via; Helena I M Boshoff; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

Review 4.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  PA-824 exhibits time-dependent activity in a murine model of tuberculosis.

Authors:  Zahoor Ahmad; Charles A Peloquin; Rajendra P Singh; Hartmut Derendorf; Sandeep Tyagi; Ann Ginsberg; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

6.  Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.

Authors:  Rovina Ruslami; Hanneke M J Nijland; Bachti Alisjahbana; Ida Parwati; Reinout van Crevel; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

7.  Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses.

Authors:  Pooja Gupta; Vandana Roy; Gulshan Rai Sethi; Tarun Kumar Mishra
Journal:  Br J Clin Pharmacol       Date:  2007-12-17       Impact factor: 4.335

8.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

9.  Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA.

Authors:  Scott K Heysell; Jane L Moore; Suzanne J Keller; Eric R Houpt
Journal:  Emerg Infect Dis       Date:  2010-10       Impact factor: 6.883

10.  Assessing the risk of birth defects associated with exposure to fixed-dose combined antituberculous agents during pregnancy in rats.

Authors:  O Awodele; E B Patrick; Esther Oluwatoyin Agbaje; A A Oremosu; S C Gbotolorun
Journal:  ScientificWorldJournal       Date:  2012-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.